Eyepoint Pharmaceuticals (EYPT) Short Interest Ratio & Short Volume $9.83 +0.17 (+1.80%) Closing price 07/3/2025 02:34 PM EasternExtended Trading$9.84 +0.00 (+0.01%) As of 07/3/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Eyepoint Pharmaceuticals Short Interest DataEyepoint Pharmaceuticals (EYPT) has a short interest of 6.74 million shares, representing 10.25% of the float (the number of shares available for trading by the public). This marks a -6.00% decrease in short interest from the previous month. The short interest ratio (days to cover) is 8.1, indicating that it would take 8.1 days of the average trading volume of 815,241 shares to cover all short positions.Current Short Interest6,740,000 sharesPrevious Short Interest7,170,000 sharesChange Vs. Previous Month-6.00%Dollar Volume Sold Short$60.86 millionShort Interest Ratio8.1 Days to CoverLast Record DateJune 15, 2025Outstanding Shares68,810,000 sharesShort Percent of Float10.25%Today's Trading Volume332,554 sharesAverage Trading Volume815,241 sharesToday's Volume Vs. Average41% Short Selling Eyepoint Pharmaceuticals? Sign up to receive the latest short interest report for Eyepoint Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartEYPT Short Interest Over TimeEYPT Days to Cover Over TimeEYPT Percentage of Float Shorted Over Time Eyepoint Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/20256,740,000 shares $60.86 million -6.0%10.3%8.1 $9.03 5/31/20257,170,000 shares $51.70 million -0.6%11.0%8.6 $7.21 5/15/20257,210,000 shares $41.24 million -28.4%11.1%9.2 $5.72 4/30/202510,070,000 shares $68.68 million -14.8%N/A12.4 $6.82 4/15/202511,820,000 shares $67.02 million +8.1%18.2%14 $5.67 3/31/202510,930,000 shares $59.24 million +0.9%16.8%12.8 $5.42 3/15/202510,830,000 shares $70.61 million +0.9%16.7%12.6 $6.52 2/28/202510,730,000 shares $67.28 million -3.3%16.5%12.4 $6.27 2/15/202511,090,000 shares $72.09 million +3.5%17.1%12.3 $6.50 1/31/202510,720,000 shares $82.01 million +1.3%N/A11.9 $7.65 Get the Latest News and Ratings for EYPT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eyepoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/202510,580,000 shares $81.36 million +2.3%N/A11 $7.69 12/31/202410,340,000 shares $77.03 million +9.9%N/A10.8 $7.45 12/15/20249,410,000 shares $70.20 million +1.7%N/A10.3 $7.46 11/30/20249,250,000 shares $81.86 million -6.4%N/A10.8 $8.85 11/15/20249,880,000 shares $90.60 million +2.1%N/A12.2 $9.17 10/31/20249,680,000 shares $113.84 million +5.6%N/A13.1 $11.76 10/15/20249,170,000 shares $90.60 million +2.7%N/A15.9 $9.88 9/30/20248,930,000 shares $71.35 million -1.9%N/A13.8 $7.99 9/15/20249,100,000 shares $82.81 million -0.1%N/A12.8 $9.10 8/31/20249,110,000 shares $81.53 million -3.9%N/A12.6 $8.95 8/15/20249,480,000 shares $77.74 million -0.7%N/A11.6 $8.20 7/31/20249,550,000 shares $94.35 million -5.3%N/A10.7 $9.88 7/15/202410,080,000 shares $106.24 million +4.7%N/A8.8 $10.54 6/30/20249,630,000 shares $83.78 million +7.2%N/A8.5 $8.70 6/15/20248,980,000 shares $84.23 million +16.0%N/A8.2 $9.38 5/31/20247,740,000 shares $82.90 million -4.8%N/A6.7 $10.71 5/15/20248,130,000 shares $105.20 million +23.2%N/A7 $12.94 4/30/20246,600,000 shares $116.16 million +0.9%N/A5.6 $17.60 4/15/20246,540,000 shares $139.17 million -4.5%N/A6.7 $21.28 3/31/20246,850,000 shares $141.59 million +4.1%N/A7.1 $20.67 3/15/20246,580,000 shares $141.34 million +15.0%N/A6.4 $21.48 2/29/20245,720,000 shares $155.64 million +20.4%N/A4.5 $27.21 2/15/20244,750,000 shares $138.13 million -7.6%N/A2.9 $29.08 1/31/20245,140,000 shares $138.42 million -1.2%N/A3.3 $26.93 1/15/20245,200,000 shares $118.35 million -2.4%N/A3.5 $22.76 12/31/20235,330,000 shares $123.18 million +12.2%N/A3.9 $23.11 12/15/20234,750,000 shares $92.86 million -32.2%N/A3.6 $19.55 11/30/20237,010,000 shares $43.81 million +28.9%25.0%5.9 $6.25 11/15/20235,440,000 shares $36.39 million +1.7%19.4%10.3 $6.69 10/31/20235,350,000 shares $32.21 million +9.0%19.2%10.3 $6.02Presidential Bombshell: $150T Resource to Be Released as soon as this Summer? (Ad)Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.We recently interviewed Rickards to get the full story and understand how everyday Americans can pre 10/15/20234,910,000 shares $39.77 million -29.3%17.6%9.3 $8.10 9/30/20236,940,000 shares $55.45 million +12.3%25.1%11.6 $7.99 9/15/20236,180,000 shares $64.77 million +9.2%22.3%10.2 $10.48 8/31/20235,660,000 shares $56.09 million +12.1%20.6%9.5 $9.91 8/15/20235,050,000 shares $71.66 million +3.7%18.8%8.9 $14.19 7/31/20234,870,000 shares $60.88 million +1.9%N/A9.3 $12.50 7/15/20234,780,000 shares $52.44 million -7.7%N/A4.9 $10.97 6/30/20235,180,000 shares $45.07 million +7.5%N/A5.6 $8.70 6/15/20234,820,000 shares $32.73 million +13.2%18.4%5.3 $6.79 5/31/20234,260,000 shares $25.77 million +5.2%16.2%4.8 $6.05 5/15/20234,050,000 shares $24.30 million +11.3%15.4%4.7 $6.00 4/30/20233,640,000 shares $22.86 million -0.3%14.1%4.4 $6.28 4/15/20233,650,000 shares $15.80 million +9.3%14.2%5.3 $4.33 3/31/20233,340,000 shares $9.82 million +19.7%13.0%11 $2.94 3/15/20232,790,000 shares $6.67 million +34.8%10.9%10 $2.39 2/28/20232,070,000 shares $6.91 million No Change8.1%8.1 $3.34 2/15/20232,070,000 shares $7.66 million -4.2%8.1%8.5 $3.70 1/31/20232,160,000 shares $10.07 million +6.9%8.6%9.3 $4.66 1/15/20232,020,000 shares $10.18 million +13.5%8.0%9.4 $5.04 12/30/20221,780,000 shares $6.23 million +6.0%7.1%12.3 $3.50 12/15/20221,680,000 shares $4.50 million -2.9%6.7%11.6 $2.68 11/30/20221,730,000 shares $5.54 million -3.4%6.9%13.6 $3.20 11/15/20221,790,000 shares $7.91 million -9.1%7.1%14.1 $4.42 10/31/20221,970,000 shares $10.64 million -1.5%N/A16.1 $5.40 10/15/20222,000,000 shares $11.20 million -1.5%7.7%14.3 $5.60 9/30/20222,030,000 shares $16.06 million -0.5%7.8%12.5 $7.91 9/15/20222,040,000 shares $16.30 million +0.5%7.9%12.7 $7.99 8/31/20222,030,000 shares $20.30 million +1.5%7.8%12.7 $10.00 8/15/20222,000,000 shares $22.24 million -8.3%7.7%12.8 $11.12 7/31/20222,180,000 shares $19.90 million +7.4%8.3%13.8 $9.13 7/15/20222,030,000 shares $20.12 million +1.0%7.8%14.4 $9.91 6/30/20222,010,000 shares $15.82 million +2.0%7.7%16.8 $7.87 6/15/20221,970,000 shares $15.62 million -5.3%7.5%16.7 $7.93 5/31/20222,080,000 shares $20.07 million -3.3%8.0%16 $9.65 5/15/20222,150,000 shares $21.26 million -1.4%8.2%14.1 $9.89 4/30/20222,180,000 shares $24.63 million +0.5%8.3%13.4 $11.30 4/15/20222,170,000 shares $27.54 million +0.5%8.3%11.9 $12.69 3/31/20222,160,000 shares $26.24 million +4.9%8.3%9.6 $12.15 3/15/20222,060,000 shares $24.82 million +3.0%7.9%7.9 $12.05 2/28/20222,000,000 shares $19.90 million +3.6%7.7%7.2 $9.95 2/15/20221,930,000 shares $19.59 million -2.5%7.4%6.6 $10.15 1/31/20221,980,000 shares $18.55 million -8.3%7.6%2.4 $9.37 1/15/20222,160,000 shares $21.45 million +11.3%N/A2.7 $9.93 12/31/20211,940,000 shares $23.75 million +0.5%7.4%2.5 $12.24 12/15/20211,930,000 shares $28.27 million -3.5%7.4%2.6 $14.65 11/30/20212,000,000 shares $31.60 million +98.0%8.1%2.9 $15.80 11/15/20211,010,000 shares $14.44 million -34.0%4.2%1.5 $14.30 10/29/20211,530,000 shares $17.55 million +10.9%7.3%11 $11.47 10/15/20211,380,000 shares $15.79 million +0.7%6.6%12.1 $11.44 9/30/20211,370,000 shares $14.28 million -3.5%6.5%11.3 $10.42Presidential Bombshell: $150T Resource to Be Released as soon as this Summer? (Ad)Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.We recently interviewed Rickards to get the full story and understand how everyday Americans can pre 9/15/20211,420,000 shares $14.31 million +2.9%6.8%8.4 $10.08 8/31/20211,380,000 shares $15.10 million +4.6%6.6%8.2 $10.94 8/13/20211,320,000 shares $13.66 million -4.4%6.3%8 $10.35 7/30/20211,380,000 shares $11.34 million +5.3%6.6%8.1 $8.22 7/15/20211,310,000 shares $10.00 million +0.8%6.3%7 $7.63 6/30/20211,300,000 shares $11.69 million +14.0%6.2%6.6 $8.99 6/15/20211,140,000 shares $10.84 million -10.2%5.5%6.7 $9.51 5/28/20211,270,000 shares $12.48 million +3.3%6.1%6.6 $9.83 5/14/20211,230,000 shares $10.90 million +116.3%5.9%5.2 $8.86 4/30/2021568,700 shares $6.13 million +1.5%2.7%2.1 $10.78 4/15/2021560,300 shares $5.47 million -15.2%2.6%1.7 $9.77 3/31/2021660,700 shares $6.40 million +28.1%3.2%1.9 $9.69 3/15/2021515,600 shares $5.78 million +35.1%2.5%1.3 $11.21 2/26/2021381,700 shares $4.21 million +9.0%2.2%1 $11.03 2/12/2021350,200 shares $4.74 million +38.6%2.2%1 $13.54 1/29/2021252,600 shares $2.77 million -5.9%1.8%0.8 $10.96 1/15/2021268,500 shares $2.94 million +19.6%3.0%1.2 $10.95 12/31/2020224,500 shares $1.32 million -35.6%2.2%1 $5.90 12/15/2020348,800 shares $1.58 million -83.3%3.5%2.1 $4.53 11/30/20202,090,000 shares $11.27 million -11.8%20.8%14.5 $5.39 11/15/20202,370,000 shares $10.59 million +0.4%2.4%1.8 $4.47 10/30/20202,360,000 shares $9.13 million +15.7%2.6%0.9 $3.87 10/15/20202,040,000 shares $10.27 million -7.3%2.3%0.8 $5.03 9/30/20202,200,000 shares $11.40 million +3.8%2.6%0.9 $5.18 9/15/20202,120,000 shares $11.44 million -4.1%2.6%0.9 $5.40 8/31/20202,210,000 shares $11.83 million +14.5%2.7%0.9 $5.35 8/14/20201,930,000 shares $11.77 million -3.0%2.4%0.8 $6.10 7/31/20201,990,000 shares $14.13 million -8.7%2.4%2.2 $7.10 7/15/20202,180,000 shares $15.59 million -18.7%2.7%2.5 $7.15 EYPT Short Interest - Frequently Asked Questions What is Eyepoint Pharmaceuticals' current short interest? Short interest is the volume of Eyepoint Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of June 15th, investors have sold 6,740,000 shares of EYPT short. 10.25% of Eyepoint Pharmaceuticals' shares are currently sold short. Learn More on Eyepoint Pharmaceuticals' current short interest. What is a good short interest ratio for Eyepoint Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EYPT shares currently have a short interest ratio of 8.0. Learn More on Eyepoint Pharmaceuticals's short interest ratio. Which institutional investors are shorting Eyepoint Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Eyepoint Pharmaceuticals: Jane Street Group LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Eyepoint Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.25% of Eyepoint Pharmaceuticals' floating shares are currently sold short. Is Eyepoint Pharmaceuticals' short interest increasing or decreasing? Eyepoint Pharmaceuticals saw a decline in short interest in June. As of June 15th, there was short interest totaling 6,740,000 shares, a decline of 6.0% from the previous total of 7,170,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Eyepoint Pharmaceuticals' short interest compare to its competitors? 10.25% of Eyepoint Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "measuring and control equipment" compare to Eyepoint Pharmaceuticals: 10x Genomics (12.04%), Transcat, Inc. (5.13%), Allient Inc. (1.93%), Standard BioTools Inc. (4.42%), Cytek Biosciences, Inc. (4.44%), Senseonics Holdings, Inc. (8.14%), Aehr Test Systems (23.99%), Quantum-Si Incorporated (17.52%), 908 Devices Inc. (8.87%), Quanterix Corporation (9.88%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short Eyepoint Pharmaceuticals stock? Short selling EYPT is an investing strategy that aims to generate trading profit from Eyepoint Pharmaceuticals as its price is falling. EYPT shares are trading up $0.17 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Eyepoint Pharmaceuticals? A short squeeze for Eyepoint Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EYPT, which in turn drives the price of the stock up even further. How often is Eyepoint Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EYPT, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies 10x Genomics Short Interest Transcat Short Interest Allient Short Interest Standard BioTools Short Interest Cytek Biosciences Short Interest Senseonics Short Interest Aehr Test Systems Short Interest Quantum-Si Short Interest 908 Devices Short Interest Quanterix Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EYPT) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EYPT Stock Alerts